News

Why the Change? Inteliphage is evolving. We are no longer just a research-driven biotech – we are now fully committed to bringing next-generation bacteriophage therapies into routine clinical care for…

How bacteriophages offer a promising natural solution for tackling superbugs and antimicrobial resistance and outlines the Belgian Vésale Bioscience company’s efforts to become a pioneer in the development of innovative,…

Namur (Belgium), 5 April 2023 Can phage therapy be a realistic alternative to fight antibiotic resistance in production animals? Join us on Wednesday, April 5, starting at 9:30 am at…

Namur (Belgium), 13 January 2023 Vésale Bioscience is developing innovative precision phage therapy solutions to treat bacterial infections resistant to antibiotics, and today announces that it has received a €1.8…

Biosaxony, the Saxony’s Biotechnology, Medical Technology & Health Economy Cluster in Leipzig, has selected Vésale Bioscience for their MEDICAL FORGE Accelerator program 2023 (

CMO Dr Vincent Grek joins Vésale Bioscience as Chief Medical Officer He has a Strong Clinical Development Expertise in the biotech, nutrition and pharmaceutical industry (antibiotics, gene therapy, enzyme replacement…

Gunther Vanwezer joins the Vésale Bioscience team as Chief Executive Officer. He hold a Master degree in Biochemical Engineering Technology from the University of Leuven (Belgium). He has over 25…

Vésale Bioscience announces that it has been awarded the prize for most innovative start-up in life sciences in Europe during the tenth edition of BioFIT, which was held digitally from…

Gérald de Patoul joins the Vésale Bioscience team as Chief Business Development Officer. He co-founded of Oncomfort in May 2017 and acted for 4 years as Director and CFO, in…

Visit of Mr David Clarinval, Minister for the Middle Classes, the Self-Employed, SMEs, Agriculture, Institutional Reforms & Democratic Renewal. The minister met with Vésale Bioscience Executive Team to discuss how…